AU772911B2 - Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders - Google Patents
Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders Download PDFInfo
- Publication number
- AU772911B2 AU772911B2 AU44322/99A AU4432299A AU772911B2 AU 772911 B2 AU772911 B2 AU 772911B2 AU 44322/99 A AU44322/99 A AU 44322/99A AU 4432299 A AU4432299 A AU 4432299A AU 772911 B2 AU772911 B2 AU 772911B2
- Authority
- AU
- Australia
- Prior art keywords
- secretin
- individual
- effective amount
- disorder
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2235—Secretins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8857598P | 1998-06-09 | 1998-06-09 | |
| US60/088575 | 1998-06-09 | ||
| US09/229208 | 1999-01-13 | ||
| US09/229,208 US6197746B1 (en) | 1998-05-19 | 1999-01-13 | Method of using secretin for treating autism |
| PCT/US1999/013061 WO1999064059A2 (en) | 1998-06-09 | 1999-06-09 | Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU4432299A AU4432299A (en) | 1999-12-30 |
| AU772911B2 true AU772911B2 (en) | 2004-05-13 |
Family
ID=26778819
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU44322/99A Ceased AU772911B2 (en) | 1998-06-09 | 1999-06-09 | Use of secretin for the treatment of autism and other neurological, behavioral and immunological disorders |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US6197746B1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1085901B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2002517467A (cg-RX-API-DMAC7.html) |
| AT (1) | ATE322283T1 (cg-RX-API-DMAC7.html) |
| AU (1) | AU772911B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2333657A1 (cg-RX-API-DMAC7.html) |
| DE (1) | DE69930739D1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO1999064059A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| US6020310A (en) * | 1997-05-19 | 2000-02-01 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
| US6020314A (en) * | 1998-08-11 | 2000-02-01 | Milkhaus Laboratory, Inc. | Methods for treatment of neurological disorders |
| WO2001037801A1 (en) * | 1999-11-22 | 2001-05-31 | Rogoff Joseph A | Secretin and secretin pharmaceuticals for treating attention deficit disorder |
| US6632429B1 (en) * | 1999-12-17 | 2003-10-14 | Joan M. Fallon | Methods for treating pervasive development disorders |
| US6534063B1 (en) | 1999-12-17 | 2003-03-18 | Joan M. Fallon | Methods for treating pervasive development disorders |
| GB0008326D0 (en) * | 2000-04-06 | 2000-05-24 | Shs International Ltd | Diagnosis and treatment of autism and related disorders |
| GB0016441D0 (en) | 2000-07-04 | 2000-08-23 | Pharmagene Lab Limited | Therapeutic method |
| US20070053895A1 (en) | 2000-08-14 | 2007-03-08 | Fallon Joan M | Method of treating and diagnosing parkinsons disease and related dysautonomic disorders |
| US6660831B2 (en) * | 2000-08-14 | 2003-12-09 | Joan M. Fallon | Method for diagnosing and treating dysautonomia and other dysautonomic conditions |
| CA2419285C (en) * | 2000-08-25 | 2011-08-02 | Research Corporation Technologies, Inc. | New uses for amino acid anticonvulsants |
| US8030002B2 (en) | 2000-11-16 | 2011-10-04 | Curemark Llc | Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions |
| GB0118383D0 (en) * | 2001-07-27 | 2001-09-19 | Pharmagene Lab Ltd | Therapeutic methods |
| US6585996B1 (en) | 2002-03-13 | 2003-07-01 | Westlake Laboratories, Inc. | Lipid-soluble thiamine derivatives in the treatment of autism |
| US8100844B2 (en) * | 2002-04-25 | 2012-01-24 | Ultraflex Systems, Inc. | Ambulating ankle and knee joints with bidirectional dampening and assistance using elastomeric restraint |
| US20070154534A1 (en) * | 2003-03-12 | 2007-07-05 | Sheitman Brian B | Use of secretin in the treatment of schizophrenia |
| EP1605960A2 (en) * | 2003-03-12 | 2005-12-21 | Repligen Corporation | Use of secretin and secretin analogs to treat affective disorders |
| US8524665B2 (en) * | 2003-05-13 | 2013-09-03 | The Mclean Hospital Corporation | Use of secretin in treatments of disorders associated with the amygdala |
| US7947285B2 (en) * | 2003-12-12 | 2011-05-24 | Fein Seymour H | Methods for preventing post endoscopic retrograde cholangiopancreatography pancreatitis |
| US7381698B2 (en) * | 2003-12-12 | 2008-06-03 | Chirhoclin, Inc. | Methods for treatment of acute pancreatitis |
| US20060198838A1 (en) * | 2004-09-28 | 2006-09-07 | Fallon Joan M | Combination enzyme for cystic fibrosis |
| GB0504096D0 (en) * | 2005-02-28 | 2005-04-06 | Tipogen As | Method |
| US20070034214A1 (en) * | 2005-08-12 | 2007-02-15 | Dochniak Michael J | Method to affect the development of autism spectrum disorders |
| US20080058282A1 (en) | 2005-08-30 | 2008-03-06 | Fallon Joan M | Use of lactulose in the treatment of autism |
| US20070116695A1 (en) * | 2005-09-21 | 2007-05-24 | Fallon Joan M | Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders |
| US8658163B2 (en) | 2008-03-13 | 2014-02-25 | Curemark Llc | Compositions and use thereof for treating symptoms of preeclampsia |
| US8084025B2 (en) | 2008-04-18 | 2011-12-27 | Curemark Llc | Method for the treatment of the symptoms of drug and alcohol addiction |
| US20090324730A1 (en) * | 2008-06-26 | 2009-12-31 | Fallon Joan M | Methods and compositions for the treatment of symptoms of complex regional pain syndrome |
| US9320780B2 (en) * | 2008-06-26 | 2016-04-26 | Curemark Llc | Methods and compositions for the treatment of symptoms of Williams Syndrome |
| PL2318035T3 (pl) * | 2008-07-01 | 2019-10-31 | Curemark Llc | Sposoby i kompozycje do leczenia objawów zaburzeń neurologicznych i zaburzeń zdrowia psychicznego |
| US10776453B2 (en) * | 2008-08-04 | 2020-09-15 | Galenagen, Llc | Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain |
| US20100092447A1 (en) | 2008-10-03 | 2010-04-15 | Fallon Joan M | Methods and compositions for the treatment of symptoms of prion diseases |
| JP5684725B2 (ja) | 2009-01-06 | 2015-03-18 | キュレロン リミテッド ライアビリティ カンパニー | 黄色ブドウ球菌感染の治療または予防のための組成物および方法ならびに表面上にいる黄色ブドウ球菌の根絶または低減のための組成物および方法 |
| CA2747703C (en) | 2009-01-06 | 2021-06-15 | Curemark Llc | Compositions and methods for the treatment or the prevention of infections by e. coli |
| US9056050B2 (en) | 2009-04-13 | 2015-06-16 | Curemark Llc | Enzyme delivery systems and methods of preparation and use |
| EP2485744A4 (en) * | 2009-10-09 | 2014-01-22 | Prothera Inc | COMPOSITIONS AND METHODS COMPRISING THE PEDIOCOCCUS TO REDUCE AT LEAST ONE SYMPTOM ASSOCIATED WITH DEVELOPMENT-INVASIVE DISORDER IN A PERSON IN WHICH A DEVELOPMENT-INVASIVE DISORDER HAS BEEN DIAGNOSED |
| US9511125B2 (en) | 2009-10-21 | 2016-12-06 | Curemark Llc | Methods and compositions for the treatment of influenza |
| US20130018059A1 (en) * | 2010-03-31 | 2013-01-17 | Abela Pharmaceuticals, Inc. | Dimethyl sulfoxide (dmso) formulations for treating autism |
| US9931365B2 (en) | 2010-09-28 | 2018-04-03 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| US8962042B2 (en) | 2010-09-28 | 2015-02-24 | Lisa Geng | Methods for treating neurological disorders using nutrient compositions |
| DK2701733T3 (da) | 2011-04-21 | 2019-05-27 | Curemark Llc | Forbindelser til behandling af neuropsykiatriske forstyrrelser |
| US9442092B2 (en) | 2011-06-20 | 2016-09-13 | Kerry Lane | Methods for treatment of autism |
| US10350278B2 (en) | 2012-05-30 | 2019-07-16 | Curemark, Llc | Methods of treating Celiac disease |
| WO2018191233A1 (en) | 2017-04-10 | 2018-10-18 | Curemark, Llc | Compositions for treating addiction |
| US11318190B2 (en) | 2017-05-05 | 2022-05-03 | United States Government As Represented By The Department Of Veterans Affairs | Methods and compositions for treating liver disease |
| CN109908120B (zh) * | 2019-04-22 | 2022-04-19 | 井冈山大学 | 一种狭顶鳞毛蕨有效成分、提取方法及其应用 |
| US11541009B2 (en) | 2020-09-10 | 2023-01-03 | Curemark, Llc | Methods of prophylaxis of coronavirus infection and treatment of coronaviruses |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833722A (en) * | 1971-03-16 | 1974-09-03 | D Graybill | Method for controlling allergies |
| WO1998052593A1 (en) * | 1997-05-19 | 1998-11-26 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5029005B2 (cg-RX-API-DMAC7.html) * | 1972-05-08 | 1975-09-19 | ||
| US3987014A (en) | 1974-01-10 | 1976-10-19 | Becton, Dickinson And Company | Secretin intermediates and derivatives |
| DE2615229C2 (de) | 1976-04-08 | 1984-05-24 | Hoechst Ag, 6230 Frankfurt | Verfahren zur Herstellung und Reinigung von Sekretin |
| US4086220A (en) | 1976-08-09 | 1978-04-25 | G. D. Searle & Co. | Fragments of secretin |
| EP0021184B1 (de) | 1979-06-13 | 1984-02-08 | Hoechst Aktiengesellschaft | Sekretinpräparate mit verstärkter und protrahierter Wirkung, Verfahren zu ihrer Herstellung sowie Dihydroxybenzoyl-L-tyrosin |
| NZ196349A (en) | 1980-03-07 | 1984-08-24 | Interx Research Corp | Enhancement of absorption rate of orally administered polar bioactive agents |
| JPS58140024A (ja) | 1982-02-15 | 1983-08-19 | Eisai Co Ltd | セクレチンの精製方法 |
| DE3328793A1 (de) | 1983-08-10 | 1985-02-28 | Hoechst Ag, 6230 Frankfurt | Herstellung von sekretin |
| SE454513B (sv) | 1985-03-11 | 1988-05-09 | Kabigen Ab | Humant sekretin samt kompositioner innehallande detta |
| JPS61277618A (ja) | 1985-06-04 | 1986-12-08 | Suntory Ltd | 自閉症治療剤 |
| US5008251A (en) | 1986-03-27 | 1991-04-16 | The Regents Of The University Of California | Method of treating autism |
| US4994467A (en) | 1989-05-31 | 1991-02-19 | Zimmerman Andrew W | Treating autism and other developmental disorders in children with NMDA receptor antagonists |
| US5094837A (en) | 1990-01-22 | 1992-03-10 | Wayne State University | Method for use of magnetic resonance imaging to image pancreas using secretin |
| US5225407A (en) | 1990-02-22 | 1993-07-06 | Glaxo Group Limited | 5-HT3 receptor antagonists for the treatment of autism |
| US5380872A (en) * | 1992-07-14 | 1995-01-10 | Glaxo Inc. | Modulators of cholecystokinin |
| ES2154673T3 (es) | 1993-01-29 | 2001-04-16 | Aradigm Corp | Suministro intrapulmonar de hormonas. |
| US5527825A (en) | 1994-04-06 | 1996-06-18 | University Of Arkansas | Method of treating schizophrenia, tourette's syndrome, mania, autism, and obsessive compulsive disorder with inhibitors of brain nitric oxide synthase |
| US5560910A (en) * | 1994-08-26 | 1996-10-01 | Crandall; Wilson T. | Topical anti-inflammatory composition and method |
| GB9417524D0 (en) | 1994-08-31 | 1994-10-19 | Cortecs Ltd | Pharmaceutical compositions |
| US5686311A (en) | 1995-06-23 | 1997-11-11 | The Children's Mercy Hospital | Diagnosis of autism and treatment therefor |
| US6197746B1 (en) * | 1998-05-19 | 2001-03-06 | Repligen Corporation | Method of using secretin for treating autism |
| CA2303484A1 (en) | 1997-09-11 | 1999-03-18 | The Regents Of The University Of California | Plus end-directed microtubule motor required for chromosome congression |
-
1999
- 1999-01-13 US US09/229,208 patent/US6197746B1/en not_active Expired - Fee Related
- 1999-06-09 CA CA002333657A patent/CA2333657A1/en not_active Abandoned
- 1999-06-09 JP JP2000553127A patent/JP2002517467A/ja not_active Withdrawn
- 1999-06-09 AT AT99927416T patent/ATE322283T1/de not_active IP Right Cessation
- 1999-06-09 EP EP99927416A patent/EP1085901B1/en not_active Expired - Lifetime
- 1999-06-09 AU AU44322/99A patent/AU772911B2/en not_active Ceased
- 1999-06-09 DE DE69930739T patent/DE69930739D1/de not_active Expired - Lifetime
- 1999-06-09 WO PCT/US1999/013061 patent/WO1999064059A2/en not_active Ceased
-
2001
- 2001-03-05 US US09/800,431 patent/US6790825B2/en not_active Expired - Fee Related
-
2003
- 2003-08-08 US US10/637,250 patent/US20050249714A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3833722A (en) * | 1971-03-16 | 1974-09-03 | D Graybill | Method for controlling allergies |
| WO1998052593A1 (en) * | 1997-05-19 | 1998-11-26 | Repligen Corporation | Method for assisting in differential diagnosis and treatment of autistic syndromes |
Non-Patent Citations (1)
| Title |
|---|
| HORVATH (1998) J. ASSOC ACA. MIN. PHYS. V9(1) P 9-15 * |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1085901B1 (en) | 2006-04-05 |
| US6790825B2 (en) | 2004-09-14 |
| US20050249714A1 (en) | 2005-11-10 |
| US6197746B1 (en) | 2001-03-06 |
| DE69930739D1 (de) | 2006-05-18 |
| WO1999064059A3 (en) | 2000-03-02 |
| US20010049353A1 (en) | 2001-12-06 |
| ATE322283T1 (de) | 2006-04-15 |
| JP2002517467A (ja) | 2002-06-18 |
| EP1085901A2 (en) | 2001-03-28 |
| AU4432299A (en) | 1999-12-30 |
| CA2333657A1 (en) | 1999-12-16 |
| WO1999064059A2 (en) | 1999-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6197746B1 (en) | Method of using secretin for treating autism | |
| Chebli | Treatment of seasonal depression with d-fenfluramine | |
| US4432975A (en) | Process for introducing vitamin B-12 into the bloodstream | |
| Aird et al. | Anticonvulsive properties of desoxycorticosterone | |
| JP2014506254A (ja) | β−ヒドロキシ−β−メチルブチレートを用いる廃用期間後の筋肉回復を促進させるための方法 | |
| MIER et al. | Acanthrocytosis, pigmentary degeneration of the retina and ataxic neuropathy: a genetically determined syndrome with associated metabolic disorder | |
| JP2002501616A (ja) | 自閉的症候群を鑑別診断および治療する際の助けとするための方法 | |
| Dropcho et al. | Paraneoplastic opsoclonus-myoclonus: association with medullary thyroid carcinoma and review of the literature | |
| CN1711101A (zh) | 孤独症及相似障碍的治疗 | |
| US20100168053A1 (en) | Oral delivery system for methylcobalamin to treat disorders | |
| Bienfang | Opsoclonus in infancy | |
| CN114306207A (zh) | 一种以棒棒糖为载体的口腔给药方法 | |
| Brownell et al. | Degeneration of muscle in association with carcinoma of the bronchus. | |
| US11564958B2 (en) | Compositions and methods of treatment of Ehlers-Danlos syndromes | |
| CN119212574A (zh) | 用于降低血糖的水解胶原蛋白 | |
| Loeb | The venom of Heloderma | |
| Restivo et al. | Trismus after stroke/TBI: botulinum toxin benefit and use pre-PEG placement | |
| RU2153891C2 (ru) | Способ лечения эпилепсии у детей | |
| Frucht et al. | Unusual Movement Disorders | |
| RU2329761C2 (ru) | Способ лечения абсансов при идиопатической генерализованной эпилепсии у детей | |
| EP0012774A1 (en) | Vegetative stigmata therapeutic agent | |
| RU2219936C2 (ru) | Способ лечения хронического слухового галлюциноза, резистентного к терапии | |
| RU2548712C2 (ru) | Способ лечения эпилепсий | |
| WO2001037801A1 (en) | Secretin and secretin pharmaceuticals for treating attention deficit disorder | |
| Shulman | That Imitate Epilepsy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |